Angiostatic Treatment for Retinal Disease: Understanding New Data and Real-World Outcomes (CME Webcast)
Activity Description and Purpose
This educational activity is intended to provide a real-world perspective on new treatment approaches being used to address the underlying pathophysiology of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Expert faculty will review the latest data for treating nAMD and DME, focusing on angiostatic treatments. Case-based discussions will include identification of patients who may benefit from new approaches to treat their nAMD or DME and how to design treatment plans that reflect best practices and real-world data. Fresh perspectives from retina specialists who are early in their career will provide unique insights. The desired results of this educational activity are for retina specialists and other ophthalmologists to become familiar with the mechanism of action and efficacy and safety evidence of clinical trials and real-world studies of new treatments for nAMD or DME to improve the treatment burden and outcomes of their patients.
This educational activity is intended for retina specialists and other ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the pathophysiologic mechanisms of new approaches to treating neovascular age-related macular degeneration and diabetic macular edema
- Review the latest data for treating neovascular age-related macular degeneration and diabetic macular edema
- Design treatment plans for patients who would be good candidates for new approaches to treat their neovascular age-related macular degeneration or diabetic macular edema
Aleksandra V. Rachitskaya, MD (Chair)
|Roger A. Goldberg, MD, MBA
Bay Area Retina Associates
Walnut Creek, California
|Katherine Talcott, MD
Cole Eye Institute
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Roger A. Goldberg, MD, MBA, is a consultant for AbbVie Inc, Annexon Inc, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, and Regeneron Pharmaceuticals, Inc; is an advisory board member of Boehringer Ingelheim International GmbH, Genentech, Inc, and Outlook Therapeutics, Inc; is on the speakers bureau for Apellis Pharmaceuticals, Biogen Idec, and Genentech, Inc; and is a contracted researcher for AffaMed Therapeutics, Annexon Inc, Apellis Pharmaceuticals, Boehringer Ingelheim International GmbH, EyePoint Pharmaceuticals, Genentech, Inc, Janssen, and Neurotech Pharmaceuticals.
Aleksandra V. Rachitskaya, MD, is a consultant for AbbVie Inc, Alcon, Apellis Pharmaceuticals, Genentech, Inc, Iveric Bio, Inc, Novartis Pharmaceuticals Corporation*, and Zeiss; is on the speakers bureau for Apellis Pharmaceuticals and Genentech, Inc; and is a contracted researcher for AGTC, Apellis Pharmaceuticals, Genentech, Inc, and Novartis Pharmaceuticals Corporation*.
Katherine Talcott, MD, is an advisory board member of Alimera Sciences, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, and Genentech, Inc; is on the speakers bureau for Genentech, Inc, and Iveric Bio, Inc; and is a contracted researcher for Regeneron Pharmaceuticals, Inc, Regenexbio Inc, and Zeiss.
* The financial relationship existed during the past 24 months but has now ended
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Medical Writer: Mayoni Ranasinghe MBBS, MPH, was an independent contractor for AbbVie Inc, Amneal Pharmaceuticals LLC, Argenx, Bayer AG, Boehringer Ingelheim International GmbH, and Sanofi within the past 2 years but those relationships have ended.
Other MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Genentech, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.
©2023 MedEdicus LLC. 299
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation